Psychedelic-assisted therapy is a growing avenue for addressing mental health conditions such as treatment-resistant depression, and more progress is expected in the coming years. On today’s episode of the Business Group on Health podcast, we’re joined by Andrew Penn, a leader in the study and practice of psychedelic-assisted psychotherapy.

Penn discusses the latest developments in the rapidly evolving world of psychopharmacology, including a new drug application submitted to the Food and Drug Administration in late 2023, designed to treat post-traumatic stress disorder. Penn describes the patient experience during psychedelic-assisted therapy, the integral role of nurses in current and future care models, and projections for future treatment innovation.

Thank you to today’s episode sponsor ComPsych.

Guest: Andrew Penn | Psychiatric Nurse Practitioner and Clinical Professor, University of California, San Francisco

Tags: Business Group on Health, psilocybin, psychedelic, psychedelic-assisted therapy, psychedelic-assisted treatment, psychotherapy.
 
Posted in: Audio Podcast, Business Group on Health, Healthcare